Weiheng Hu

Circulating <scp>PD</scp>‐<scp>L</scp>1 in <scp>NSCLC</scp> patients and the correlation between the level of <scp>PD</scp>‐<scp>L</scp>1 expression and the clinical characteristics

Jie Zhang, Jing Gao, Yanyan Li et al. · Thoracic Cancer · 2015 · 124 citations · Full text

Medicine, Cancer Biology, Oncology +16

Salvage treatment with anlotinib for advanced non‐small cell lung cancer

Di Wu, Jun Nie, Ling Dai et al. · Thoracic Cancer · 2019 · 37 citations · Full text

Medicine, Oncology, Pharmacology +14

Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients

Xiangjuan Ma, Ziran Zhang, Xiaoling Chen et al. · Thoracic Cancer · 2021 · 35 citations · Full text

Medicine, Oncology, Chemotherapy +12

A phase <scp>II</scp> study of anlotinib in 45 patients with relapsed small cell lung cancer

Di Wu, Jun Nie, Weiheng Hu et al. · International Journal of Cancer · 2020 · 34 citations · Full text

Medicine, Oncology, Pharmacology +15

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China

Xiaoling Chen, Jun Nie, Ling Dai et al. · Frontiers in Oncology · 2021 · 32 citations · Full text

Medicine, Oncology, Pharmacology +16